Search Results - "Heimberger, A"

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types by McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Lim, B., Ueno, N.T., Litton, J.K., Ferrarotto, R., Chang, J.T., Moulder, S.L., Lin, S.-Y.

“…High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential…”
Get full text

Disconnected Pancreatic Duct Syndrome: Spectrum of Operative Management by Maatman, Thomas K., Roch, Alexandra M., Lewellen, Kyle A., Heimberger, Mark A., Ceppa, Eugene P., House, Michael G., Nakeeb, Attila, Schmidt, C. Max, Zyromski, Nicholas J.

“…Disconnected pancreatic duct syndrome (DPDS) is common after necrotizing pancreatitis (NP). Surgical management may be by internal drainage or left (distal)…”
Get full text

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay by McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Ueno, N.T., Ferrarotto, R., Chang, J.T., Lin, S.-Y.

Get full text

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al by McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Ueno, N.T., Ferrarotto, R., Chang, J.T., Lin, S.-Y.

Get full text

Postoperative Stereotactic Radiosurgery Versus Observation for Completely Resected Brain Metastases: Results of a Prospective Randomized Study by Mahajan, A, Ahmed, S, Li, J, McAleer, M.F, Weinberg, J, Brown, P.D, Prabhu, S, Lang, F.F, McGovern, S.L, McCutcheon, I.E, Heimberger, A, Sulman, E.P, Ghia, A.J, Ferguson, S, Hess, K, Rao, G

Get full text

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study by Schuster, James, Lai, Rose K, Recht, Lawrence D, Reardon, David A, Paleologos, Nina A, Groves, Morris D, Mrugala, Maciej M, Jensen, Randy, Baehring, Joachim M, Sloan, Andrew, Archer, Gary E, Bigner, Darell D, Cruickshank, Scott, Green, Jennifer A, Keler, Tibor, Davis, Thomas A, Heimberger, Amy B, Sampson, John H

“…The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary glioblastoma and linked to poor long-term…”
Get full text

Consensus on the role of human cytomegalovirus in glioblastoma by Dziurzynski, Kristine, Chang, Susan M, Heimberger, Amy B, Kalejta, Robert F, McGregor Dallas, Stuart R, Smit, Martine, Soroceanu, Liliana, Cobbs, Charles S

“…The human cytomegalovirus (HCMV) and glioma symposium was convened on April 17, 2011 in Washington, DC, and was attended by oncologists and virologists…”
Get full text

O6.01 TARGETING THE IMMUNE CHECKPOINT NETWORK WITH MIR-138 EXERTS THERAPEUTIC EFFICACY IN MURINE MODELS OF GLIOMA by Heimberger, A., Wei, J., Nduom, E., Kong, L., Ivan, C., Fuller, G. N., Gilbert, M. R., Conrad, C. A., Calin, G. A.

“…Antibody therapeutic targeting of the immune checkpoints CTLA-4 and PD-1 has demonstrated marked tumor regression in clinical trials; however, this requires…”
Get full text

Epidermal growth factor receptor and variant III targeted immunotherapy by Congdon, Kendra L, Gedeon, Patrick C, Suryadevara, Carter M, Caruso, Hillary G, Cooper, Laurence J N, Heimberger, Amy B, Sampson, John H

“…Immunotherapeutic approaches to cancer have shown remarkable promise. A critical barrier to successfully executing such immune-mediated interventions is the…”
Get full text

Lung biopsy in children's interstitial and diffuse lung disease: Does it alter management? by Hafezi, Niloufar, Heimberger, Mark A., Lewellen, Kyle A., Maatman, Thomas, Montgomery, Gregory S., Markel, Troy A.

“…Introduction Pediatric patients with acute life‐threatening consequences of interstitial and diffuse lung disease are often treated with empiric systemic…”
Get full text

High Rates of Readmission in Necrotizing Pancreatitis: Natural History or Opportunity for Improvement? by Maatman, Thomas K., Mahajan, Sarakshi, Roch, Alexandra M., Lewellen, Kyle A., Heimberger, Mark A., Colgate, Cameron L., Ceppa, Eugene P., House, Michael G., Nakeeb, Attila, Schmidt, C. Max, Zyromski, Nicholas J.

“…Background Necrotizing pancreatitis (NP) is a complex and heterogeneous disease with a protracted disease course. Hospital readmission is extremely common;…”
Get full text

Visceral artery pseudoaneurysm in necrotizing pancreatitis: incidence and outcomes by Maatman, Thomas K, Heimberger, Mark A, Lewellen, Kyle A, Roch, Alexandra M, Colgate, Cameron L, House, Michael G, Nakeeb, Attila, Ceppa, Eugene P, Schmidt, C Max, Zyromski, Nicholas J

“…Visceral artery pseudoaneurysms (VA-PSA) occur in necrotizing pancreatitis; however, little is known about their natural history. This study sought to evaluate…”
Get full text

Pancreatic Adenocarcinoma Causing Necrotizing Pancreatitis: Not as Rare as You Think? by Lewellen, Kyle A., Maatman, Thomas K., Heimberger, Mark A., Ceppa, Eugene P., House, Michael G., Nakeeb, Attila, Schmidt, C. Max, Zyromski, Nicholas J.

“…Necrotizing pancreatitis (NP) presents a unique clinical challenge because of its complex and lengthy disease course. Pancreatic necrosis occurs in 10%-20% of…”
Get full text

Temozolomide Delivered by Intracerebral Microinfusion is Safe and Efficacious Against Malignant Gliomas in Rats by HEIMBERGER, Amy B, ARCHER, Gary E, MCLENDON, Roger E, HULETTE, Christine, FRIEDMAN, Allan H, FRIEDMAN, Henry S, BIGNER, Darell D, SAMPSON, John H

“…Intracerebral microinfusion (ICM) is an innovative technique of delivering therapeutic agents throughout large portions of the brain that circumvents the…”
Get full text

Immunology Research by Wu, A., Wei, J., Kong, L.-Y., Wang, Y., Priebe, W., Sawaya, R., Heimberger, A. B., Heimberger, A., Doucette, T., Yang, J., Rao, G., Shimato, S., Meier, L. M., Castelli, M., Canoll, P., Asslaber, M., Bruce, J. N., Anderson, D. E., Anderson, R. C., Mahlum, E. W., Jenkins, R. B., Kohanbash, G., Mintz, A. H., McKaveney, K., McDonald, H. A., Ohlfest, J. R., Okada, H., Fujita, M., Zhang, L., Liu, W., Alizadeh, D., Zhao, D., Farrukh, O., Badie, B., Raychaudhuri, B., Pellegatta, S., Cantini, G., Pisati, F., Cuppini, L., Finocchiaro, G., Albesiano, E., Han, J. E., See, A., Jackson, C., Lim, M., Nag, K., White, J., Sippel, T., Klaassen, M., Tsvankin, V., Waziri, A., Mittal, S., Zitron, I. M., Kupsky, W. J., Alkonyi, B., Sood, S., Juhasz, C.

Get full text

Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma by Heimberger, Amy B, Archer, Gary E, Crotty, Laura E, McLendon, Roger E, Friedman, Allan H, Friedman, Henry S, Bigner, Darell D, Sampson, John H

“…Dendritic cells (DCs) are specialized cells of the immune system that are capable of generating potent immune responses that are active even within the…”
Get full text

Abstract SP084: Replication stress response defects predict responses to ICT in non-hypermutated tumors by McGrail, D, Pilié, P, Zhang, XHF, Rosen, J, Voorwerk, L, Kok, M, Heimberger, A, Peterson, C, Jonasch, E, Lin, S

“…Abstract Immune checkpoint blockade (ICT) has provided robust, durable responses to a subset of patients. Many initial ICT trials were focused on highly…”
Get full text

Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma by Heimberger, Amy B, Crotty, Laura E, Archer, Gary E, McLendon, Roger E, Friedman, Allan, Dranoff, Glenn, Bigner, Darell D, Sampson, John H

“…To evaluate the efficacy and toxicity of dendritic cell (DC) based therapy for intracerebral gliomas, we utilized a cell line derived from an astrocytoma that…”
Get full text

Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma? by Heimberger, Amy B., Sampson, John H.

“…With the recent approval by the FDA of an immunotherapy for prostate cancer and another positive immunotherapy trial in melanoma, immunotherapy may finally be…”
Get full text

Temozolomide as a vaccine adjuvant in GBM by Sampson, J. H., Aldape, K. D., Gilbert, M. R., Hassenbusch, S. J., Sawaya, R., Schmittling, B., Archer, G. E., Mitchell, D., Bigner, D. D., Reardon, D. A., Heimberger, A. B.

“…Abstract only 2020 Background: Cytotoxic chemotherapy that induces lymphopenia is predicted to ablate the benefits of active antitumor immunization…”
Get full text